Bone Morphogenetic Proteins (BMPs) are multi-functional growth factors belonging to the Transforming Growth Factor-Beta (TGF-β) superfamily, which is also shared by Growth Differentiation Factors (GDFs), Glial-derived Neurotrophic Factors (GDNFs), Lefty, Inhibins, Activins, Nodal, and Mülllerian Inhibiting Substance (MIS) [1,2,3,4,5]. Currently, over 20 BMPs have been identified, making these proteins the largest subgroup within the TGF-β superfamily. BMPs have crucial functions in developmental processes, such as cardiogenesis, digit apoptosis, somite formation, neurogenesis, eye formation, and musculoskeletal development [6,7,8,9,10,11,12,13]. Additionally, BMPs are expressed throughout adulthood, contributing to osteogenesis, adipogenesis, chondrogenesis, programmed cell death, cardiac differentiation, and nervous system maintenance [14,15,16,17,18,19,20,21,22,23,24,25,26].
The first BMP was identified in bone in 1965 by Marshall Urist and named BMP-2 . Since then, BMP-2 has been well-characterized and many of its functions in bone and throughout the body have been elucidated. Because BMP-2 has been extensively studied and characterized, especially during development and in bone, this review will focus on BMP-2 in development and osteogenesis.
After identifying BMP-2, subsequent studies focused on BMP-2 and demonstrated its critical role during and after development. In early development, BMP-2 is critical for successful digit formation, cardiogenesis, neuronal growth, and many other processes [6,20,21,22,25,28,29,30]. It is continuously expressed into adulthood, where it induces processes such as intramembranous and endochondral ossification [2,27,31,32]. Additionally, BMP-2 is expressed in many cells throughout the body, such as osteocytes and osteoblasts . Further elucidating the mechanism of BMP-2, Knockouts (KOs) and conditional KOs of BMP-2 in mice led to lethality or underdeveloped bones with reduced radial bone thickness, strength, and increased risk of spontaneous fractures; further, these KOs presented heart deficiencies, chondrocyte abnormalities, and reduced vasculature [14,32,34,35,36,37].
BMP-2 has additional essential functions in the musculoskeletal system. Bone itself is a very dynamic and complex organ. The human skeleton provides protection of vital organs, structure, locomotion through anchoring of muscles, and mineral homeostasis . Five major types of bone comprise the skeleton and dependent on their size and shape, these bones exert specific functions. Classified based on their shape, they include short (carpals), flat (ribs), long (femur), irregular (vertebrae), and sesamoid bones (patella). Each of these bone types have a specific function based upon their overall shape and morphology. In addition, each bone has four major layers of bone tissue: the periosteum is the outermost protective layer; cortical or compact bone is the outer dense shell located underneath the periosteum; cancellous or trabecular bone, also known as spongy bone, is located on the inside of the cortical shell; and finally there is the marrow cavity where important or critical stem cells, such as mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs), are located [38,39]. The marrow cavity is vital, because as adults age, the locations of stem cells diminish, leading to complete reliance on the bone marrow cavities to promote differentiation of these pivotal cells. HSCs and MSCs differentiate into bone cells that are responsible for resorbing back old or damaged bone and building new bone, however, they are also responsible for differentiating cells into adipocytes or fat cells [40,41]. While adipocytes are important for bone growth and remodeling, too many fat cells within the bone are detrimental as this causes increased porosity and decreased structural support. This leads to an increase risk of fractures and breaks within the bone. Therefore, the correct balance between bone resorption, bone formation, and fat cell formation is critical for the bone remodeling process .
Bone remodeling is a critical process and it occurs continuously in the adult skeleton. In fact, approximately 10% of human bone is remodeled every year . The bone is remodeled by resorption of old bone by osteoclasts and formation of new bone by osteoblasts (). Osteoclasts in this microenvironment function as innate immune cells, initiating inflammatory responses and resorbing old or damaged bone [44,45]. When new bone needs to be formed, MSCs can differentiate into osteoblasts, and these osteoblasts can become embedded in the bone as osteocytes, which provide additional bone support and structure . The main factor that differentiates MSCs into osteoblasts is BMP-2, which is released within the bone matrix or serum during osteoclast-driven bone resorption (). To differentiate MSCs into osteoblasts, BMP-2 binds to type I and type II serine/threonine kinase receptors on target cells, activating Smad (canonical) and non-Smad (non-canonical) signaling pathways, which ultimately activates osteogenic genes such as Runt-Related Transcription Factor 2 (RUNX2) and Osterix (Osx) . Furthermore, BMP-2 is also important in stimulating osteoclastogenesis by directly differentiating osteoclast precursor cells into osteoclasts, and antagonizing BMP-2 led to the downregulation of this process [46,47]. As BMP-2 is important for MSC differentiation, osteogenesis, and osteoclastogenesis, recombinant human BMP-2 (rhBMP-2) was approved by the Food and Drug Administration (FDA) and is administered after lumbar spinal fusions in tapered or cylindrical interbody cages [48,49,50,51]. Although BMP-2 promotes fracture healing, several post-surgical complications arose, including ectopic bone formation, radiculitis, vertebral osteolysis, increased microfracture occurrence, low bone healing efficacy, and hematoma formation [48,52,53,54,55,56,57]. The molecular mechanisms implicating the ectopic bone induction process is not well understood; however, it is believed to follow a non-physiological pathway. There have been promising strides in this particular area of research, as Hashimoto and colleagues developed a novel imaging method that can help both visualize and determine ectopic bone formation pathways. This discovery will help to facilitate and direct BMP-2 induced ectopic bone formation in concert with other molecules, like PTH or IL-17; however, more research is needed . Therefore, a new treatment for bone disorders must be developed. In this review paper, we will describe the structure of BMP-2, its role in development, and its receptors, along with how it is regulated by agonists and antagonists to activate various signaling pathways. Additionally, we will describe the regulation of BMP-signaling pathways and how this regulation led to current and alternative therapeutics for bone disorders. As the FDA has approved BMP-2 for use in skeletal disorders and fractures, bone and bone disorders will be the primary focus of this review.
Figure 1. The bone microenvironment. Healthy bone function and renewal is controlled by the activity of osteoblasts and osteoclasts. Osteoblasts derive from MSCs, which commit to the osteoblast lineage after exposure to BMP-2. BMP-2 is secreted into the bone matrix or bloodstream by pre-existing osteoblasts, osteocytes, and endothelial cells, where it can bind to bone morphogenetic protein receptors (BMPRs) on MSCs. After MSCs differentiate into osteoblasts, these cells secrete the organic matrix of the bone. Some eventually become embedded within the bone as osteocytes, which provide further structure. HSCs differentiate into osteoclasts after being stimulated with factors, such as RANK-L and NF-kB. The osteoclasts are multinucleated and resorb the bone matrix, releasing contents (i.e., BMP-2 and calcium) to be recycled throughout the body.
Figure 2. Differentiation of MSCs to osteoblasts driven by BMP-2, along with the other listed factors. MSCs are located in bone marrow and differentiate into pre-osteoblasts when exposed to RUNX2 and BMP-2. The pre-osteoblasts differentiate into inactive osteoblasts in the presence of RUNX2, BMP-2, and Osx. Inactive osteoblasts become active osteoblasts in bone microenvironments that require rebuilding, and BMP-2 can also assist in this process. Active osteoblasts can then become embedded in bone and function as osteocytes.
3. BMP-2 and Development
BMP-2 has many roles during development. From the earliest stages of embryogenesis, BMP-2 regulates the formation of the dorsal/ventral (D/V) and anterior/posterior (A/P) axes [59
]. While regulating formation of the axes, BMP-2 is also involved in somite formation and somatic chondrogenesis, especially in the vertebral and axial skeleton [63
]. Further, BMP-2 is crucial in nearly every stage of neural development and is essential for closure of the neural tube [11
]. BMP-2 is also involved in the development of the optical system. Specifically, it assists in the remodeling of the sclera as well as contributing to the formation of the retinal system [13
]. However, overexpression of BMP-2 can lead to early myopia, and thus, its activity must be tightly regulated during embryogenesis and throughout development [67
]. In addition to cell patterning, neurogenesis, and eye development, BMP-2 is involved in digit formation. BMP-2 assists in programmed cell death to initiate apoptosis in distal limbs, allowing for the formation of digits; lack of BMP-2 leads to the malformation of digits [7
]. Simultaneously, BMP-2 is involved in formation of the mesoderm and in cardiogenesis [34
]. BMP-2 has a prominent role during epithelial-mesenchymal transition (EMT) and formation of myocardial cells to ensure proper heart development [6
]. BMP-2 KOs in mice led to malformation of the heart, heart valves, and irregular myocardial patterning that resulted in lethality during early embryonic stages [23
]. Further, BMP-2-deficient mice exhibited malformation of both the chorion and amnion, suggesting BMP-2’s diverse role in many cardiac developmental processes [35
]. While assisting in the cardiogenesis, BMP-2 is also involved in the formation of the pulmonary system. For example, when the lung begins to develop in early embryonic stages, BMP-2 activates BMP-signaling pathways and stimulates formation of alveolar cells and regulates pulmonary remodeling [75
]. BMP-2 also regulates pulmonary specification and branching to increase alveolar surface area [76
]. Lastly, BMP-2 is required for proper osteogenesis, chondrogenesis, and adipogenesis during development [2
]. BMP-2 is the ligand needed to activate the Smad and Non-Smad pathways that lead to bone, cartilage, and fat development; KOs or under-expression of BMP-2 result in the inability of these cells and tissues to form [18
]. Thus, BMP-2 has a prominent role in many stages of development and demonstrates its multi-functionality.
3.1. BMP-2 Receptors and Expression
Over the past decades, researchers discovered several mutations within the BMP-2
gene, revealing the importance of BMP-2 in regulating bone homeostasis and survivability. For example, mutations in the BMP-2
gene can cause altered signaling leading to brachydactyly and lethality, as downstream effector proteins and signaling pathways are not effectively activated [34
]. In order for BMP-2 to elicit its many cellular responses, it must bind to specific receptors and activate a signaling cascade. However, before investigating the functional role of BMP-2, we first must investigate how BMP-2 becomes functional (or how it is transcribed and translated). Once the BMP-2
gene is transcribed and translated, BMP-2 is not yet functional. To become active, the newly formed preproprotein undergoes proteolytic cleavage by proprotein convertase subtilisin/kexin type 5 (PCSK5) at the C-terminus [84
]. The functionally cleaved 115 amino acids (AA) BMP-2 protein is secreted from the cell to serve as an autocrine or paracrine factor, binding to receptors on both osteoblasts and osteoclasts [46
]. Once released into the bone matrix or blood, BMP-2 can be processed further by proteases. Specifically, these proteases located in the serum are able to cleave BMP-2, 4, and 7, which can de-differentiate newt muscle cells and allow them to re-enter the cell cycle. Here, the de-differentiated cells are able to commit to other cell fates, dependent on which factors they are exposed to [86
]. Further studies elucidating this mechanism in other animals should be explored.
BMP-2 binding to BMP type I and type II serine/threonine kinase receptors leads to activation of several downstream signaling pathways along with upregulation of the BMP-2
gene. Cells can express various types of receptors located on the cell surface. BMP-2 can bind to BMP receptor type Ia (BMPRIa), BMP receptor type Ib (BMPRIb), and activin receptor type Ia [88
]. BMPRIa is located on most cell surfaces while BMPRIb is less common [90
]. BMP-2 preferentially binds to preformed BMPRII-BMPRIa/b complexes or binds to BMPRIa specifically at its beta4beta5 loop, which can then oligomerize with BMPRII [93
]. Additionally, BMPRII can also oligomerize with BMPRIa/b alone when BMP-2 binds, which causes the type I receptors to oligomerize with the type II receptors and activates different signaling pathways [95
]. BMPRs are known to be expressed on both osteoblasts and osteoclasts, which is critical for bone remodeling and homeostasis. On these cells, BMP receptor signaling is also regulated by the localization of receptors in specific membrane domains. Receptors can be localized in caveolae, clathrin coated pits (CCPs), and lipid rafts located on the plasma membrane [96
]. Their localization can determine which signaling pathways are activated [96
]. Because BMPRs regulate many pathways, mutations can be detrimental. For example, in early stages of development, most gene mutations within the BMPRIa
gene result in a shorter protein sequence, which leads to inadequate BMP signaling as the specific ligands are unable to bind to BMPRs [102
has about 60 known mutations that cause juvenile polyposis syndrome, which can lead to unregulated cell growth and causes ectopic polyp formation [102
]. Additionally, BMP-2 can bind to three type II receptors, including BMP receptor type II (BMPRII), activin receptor type IIa (ActRIIa), and activin receptor type IIb [1
]. BMP-2 binds to BMPRIa with the highest affinity [94
Once BMP-2 binds to the BMPRs, phosphorylation of BMPRIa by BMPRII leads to adipogenesis, chondrogenesis, and osteogenesis, whereas phosphorylation of BMPRIb leads to apoptosis and cell death [28
]. Further, different patterns of receptor oligomerization determine the downstream pathways BMP-2 activates. For example, Smad signaling is activated when BMP-2 binds to preformed heteromeric complexes, whereas Non-Smad signaling (such as ERK) is activated when BMP-2 binds to BMPRIa and BMPRII is recruited after [18
]. Therefore, localization and oligomerization of BMPRs will determine the signaling response after BMP-2 binds. [16
In addition to BMPRs, there are co-receptors, such as BMP and activin membrane-bound inhibitor (BAMBI), Dragon, endoglin, and betaglycan that can be associated with BMPRIa, which can enhance or inhibit BMP-signaling [112
]. For example, BAMBI is a pseudoreceptor localized near BMPRs. When BMP-2 binds, the BMPRs activate BAMBI, and BAMBI decreases the BMP-signaling response as a negative regulator [116
]. Additionally, DRAGON enhances BMP-signaling during development, especially in the nervous system [119
]. Endoglin, a type 1 transmembrane glycoprotein, is a co-receptor of BMPRII and is crucial for cardiogenesis and angiogenesis, along with influencing Non-Smad signaling by affecting cell growth and adhesion [122
]. Betaglycan is a commonly expressed proteoglycan that serves as a co-receptor to BMPRII. One of its functions is to negatively regulate BMP-signaling by activating inhibin, which then associates with the receptor and prevents BMP-2 binding [125
]. Along with these co-receptors and associated proteins, previous studies have demonstrated a Heparin-binding site on BMP-2 that regulates its activity [129
]. This Heparin-binding site regulates BMP-2’s activity as when it travels through the ECM of cells, it binds to ECM proteins, such as fibronectin and tenascin C [133
]. This binding limits the migration and movement patterns of BMP-2, limiting its bioavailability and activity throughout the body, which may be useful when sustaining delivery of rhBMP-2 in clinical applications [136
]. This is further demonstrated as when this binding site is mutated, BMP-2 activity increased [129
]. This extensive regulation of BMP-2 is a combination of negative feedback, co-receptors/proteins, and binding domains.
Further, studies have demonstrated that BMP-2 is expressed in a variety of cells. By being expressed largely throughout the body, BMP-2 is able to effectively function and activate the many signaling pathways listed above. For example, BMP-2 is expressed in many tissues, including the liver and the lungs, as well as in bone (primarily in osteoblasts and osteocytes) [37
]. Additionally, BMP-2 can be paracrine or autocrine, acting as a local or systemic factor to initiate cell-to-cell responses or travelling through the serum to target cells [140
]. Further, in the absence of BMP-4, BMP-2 has been shown to compensate for its functions, especially in chondrocytes, bone, and during development [32
]. These expression patterns are vital to ensure proper maintenance of alveolar tissue, hepatocytes, developmental processes, and bone homeostasis.
3.2. BMP-2 Structure and Receptor Binding
BMP-2 was first discovered in 1965 due to its potent osteo and chondro-inductive abilities; however, the structure of BMP-2 was not crystallized until 1999. After BMP-2 was synthesized as a 453 residue proprotein, it became glycosylated and further proteolytically cleaved and dimerized. This yields the final, mature disulfide linked homodimer. Each respective monomer is 114 residues in length. A 3D rendering of the dimer’s crystallized structure revealed that the biologically active form of this protein has the dimensions of 70 Ǻ × 35 Ǻ × 30 Ǻ, where the center of the monomer is 10 Ǻ thick. Each individual monomer contains a cystine-knot formed through six cysteine residues creating three intrachain disulfide bridges. This structure is critical for BMP-2, as this provides stability that would otherwise be lacking due to the lack of a hydrophobic core. However, this is shortly resolved once the two monomers form the dimer, further stabilizing the structure of BMP-2, as well as creating extra stability through the creation of a hydrophobic core between the two monomers. The folding topography of BMP-2 features the key components of other TGF-β superfamily proteins. Briefly, they consist of two separated antiparallel β-sheets, which is made up of nine β strands. The strands do not form four antiparallel β sheets because they too far apart to participate in hydrogen bonding. The second sheet adopts a twisted crossover confirmation. There is also a four-turn α-helix which is located perpendicular to the β strands [144
BMP-2, like BMP-4, can exist in a soluble form so that it can be easily transported. When BMP-2 is in its soluble form, it binds to a lower affinity to its type II receptor, BMPRII [145
]. However, in most cases, BMP-2 preferentially binds to the type I receptors, most notably BMPRIa [21
]. In order to determine exactly how BMP-2 and BMPRIa binding is achieved and facilitated, the bound crystal structure needed to be resolved. Once crystallized, it was found that BMP-2 bound to BMPRIa through the figure-helix groove of the BMP-2 dimer. It is bound in such a way that both monomers of BMP-2 come into contact with the receptor and the C-terminus of the receptor chains are found 65 Ǻ apart. The general structure of BMPRIa can be likened to a left hand where the thumb is the helix backbone, the three extended middle fingers are the central beta sheet, and the small or pinky finger is slightly bent, indicating a loop between the β1–β2 sheets. In 2001, two binding epitopes on BMP-2 were discovered, known as the “wrist” and “knuckle” epitopes. The wrist epitope encompasses a larger area, correlating with high affinity to BMPRIa binding, while the knuckle epitope encompasses a smaller area that has low affinity for BMPRII binding. This is because binding residues located within the knuckle epitope are found in only one BMP-2 monomer, while binding residues in the wrist epitope are found in both monomers. Interestingly, the distances between the wrist and knuckle epitopes is 10–15 Ǻ, but the distances between the two receptors are much larger: 40–55 Ǻ. This distance between the two receptors helps to further stabilize the overall bound structure of BMP2 and its receptors [148
There are several regulatory feedback mechanisms which help to control BMP-2 induced activity. One of these mechanisms is through BMP antagonists, like Noggin. It was discovered that the structure and complex of Noggin inhibited BMP signaling by directly binding and blocking critical epitopes on both the type I and type II receptors. Noggin is a twelve-membered cysteine knot protein; therefore, it can mimic those wrist and knuckle epitopes that BMP-2 contains, in order to facilitate competitive binding to the BMP receptors, thus inhibiting BMP-2 induced signaling [149
]. This means both the location and proximity of the receptors is critical for proper BMP-2 binding and subsequent pathway activation [148
3.3. BMP-2 Signaling Pathways
Many important signaling pathways for osteogenesis, cell survival, and apoptosis are activated by BMP-2 [20
]. Once BMP-2 binds to BMPRs, it activates Smad and Non-Smad signaling pathways (). The Smad pathway is activated when BMPRIa and BMPRIb phosphorylate downstream proteins, namely Smad1/5/8 [109
]. The phosphorylated Smads recruit Smad4, and the complex translocates into the nucleus and acts as a transcription factor for genes, such as RUNX2
]. Additionally, in specific circumstances, BMP-2 can also activate Smad2/3 signaling through BMPRIa. In fact, Smad2/3 was preferentially activated in embryonic and transformed cells, suggesting the promiscuity of BMP-2 to regulate developmental processes and cell division [152
]. However, this process is not fully understood and BMP-2 may also exert this response in other cells. Thus, future studies should explore this area to delineate more of BMP-2’s actions and current information about the promiscuity of BMP-2 can be found in a review article by Nickel and Mueller [155
Figure 3. Bone Morphogenic Protein 2 (BMP-2) activation of signaling pathways. Once BMP-2 binds to the BMPRs located in lipid rafts, caveolae, and clathrin coated pits (CCPs), constitutively active BMPRII phosphorylates BMPRIa. This leads to downstream activation of the Smad pathway or the non-Smad pathways. In non-Smad signaling, the extracellular signal-related kinase (ERK), phosphatidylinositol 3-kinase (PI3K), and the transforming growth factor-β-activated kinase 1/binding protein 1 (TAB1/TAK1) pathways are activated. All of these pathways, except for NF-kB, lead to an increased differentiation of MSCs and osteoprogenitors into osteoblasts.
Recently, we identified Casein Kinase 2 (CK2) as a key regulator of the BMP-signaling pathway [156
]. Without the BMP-2 ligand present, CK2 is bound to BMPRIa, preventing the activation of downstream effector proteins. However, when BMP-2 is bound, CK2 is released and an upregulation of osteogenesis is observed [156
]. In the non-Smad pathway, MAPK signaling activates extracellular signal-regulated kinase (ERK), phosphatidylinositol-2 kinase (PI3K), and the TAB1/TAK1 pathways [31
]. Each of these signaling events, except for TAB1/TAK1 which activates NF-kB and p38, leads to differentiation of osteoblast precursors into osteoblasts. NF-kB has been shown to inhibit osteoblast function in osteoporotic mice models and requires further investigation [160
]. Other pathways that can be activated by BMP-2 to differentiate myoblasts and other pre-osteoblasts into osteoblasts include EIF2AK3-EIF2A-ATF4 and RhoA/Rb [162
As mentioned previously, BMPR localization on the plasma membrane determines endocytosis and which signaling pathways are activated. Previous studies first demonstrated that BMPRs were predominantly localized to CCPs [97
]. However, subsequent research indicated that BMPRs also localize to caveolae, and that caveolae are essential regulators of Smad-signaling pathways [96
]. Data demonstrated that BMP-2 preferentially binds to BMPRIa aggregates in caveolae with a higher force and frequency than CCPs to activate Smad signaling pathways [96
]. Although BMPRs are primarily found in caveolae or CCPs, they can also localize on lipid rafts [97
]. Additionally, BMP-2 has been shown to activate the Wnt signaling pathway; however, the proteins involved and whether BMP-2 induces the Wnt/β-Catenin pathway, or vice-versa, are still unknown [157
3.4. Intracellular and Extracellular Regulation of BMP-2
Signaling cascades for any cellular pathway must be regulated, and BMP-2 signaling is no different, especially due to the multiple signaling pathways activated by BMP-2. Various proteins have been identified to regulate this response. The activity of BMP-2 is enhanced or inhibited intracellularly and extracellularly. For instance, the genes Twisted gastrulation
) and Shrew
promote BMP-2 activity and enhance its activity [168
]. Further, BMP-2 is regulated intracellularly and extracellularly by several secreted antagonists. Factors such as noggin, sclerostin (SOST), and follistatin directly bind to BMP-2 in the ECM to prevent its interaction with BMPRs, especially during development [171
]. Specifically, other ECM proteins, including fibronectin, fibrinogen, and tenascin C, are able to bind to the Heparin domains of BMP-2, regulating its activity and migration [130
]. Additionally, chordin is a protein secreted from bone cells in the spine that can directly bind to BMP-2 and prevent its interaction with BMPRs [170
]. Intracellularly, inhibitory Smads (I-Smads) 6 and 7 directly regulate Smad signaling induced by BMP-2, usually by preventing downstream signaling cascades [178
]. Despite these multiple regulations, abnormal bone and cartilage loss still occurs in osteoporotic and osteoarthritic patients. The underlying mechanisms are an active area of present research, but it is hypothesized that osteoporotic patient osteoblasts have irregular BMPRIa function, leading to dysregulation of BMPR trafficking and bone homeostasis [179
]. The current identified agonists and antagonists of BMP-2 that may be involved are summarized in . Furthermore, we also include known associated proteins with BMPRs that limit the activity of BMP-2 in .
Table 1. Known agonists and antagonists of BMP-2.
Table 2. Known proteins associated with BMPRs.
3.5. Regulation of the BMP-2 Signaling Pathway by Casein Kinase 2 (CK2)
Recently, CK2 was not only identified as a key regulator of the BMP-2 pathway, but also as an inhibitor of this pathway. When inhibiting this pathway, CK2 is bound to three phosphorylation sites of BMPRIa, preventing the activation of downstream proteins [156
]. To observe the interaction of BMPRIa and CK2, we constructed mutants of BMPRIa for each phosphorylation site at specific amino acids (AA 213–217; AA 324–238; AA 475–479) were constructed [157
]. The BMPRIa mutants led to increased adipogenesis, osteogenesis, and chondrogenesis by preventing the binding of CK2 [158
]. Additionally, to understand the relation between CK2 and BMPRIa, our lab deleted the BMPRIa
gene in mice and surprisingly, this led to increased bone formation [180
]. Next, the Nohe lab designed peptides mimicking the three phosphorylation sites for BMPRIa were constructed and named CK2.1, CK2.2, and CK2.3. These peptides were able to bind and prevent CK2 from interacting with BMPRIa, leading to increased adipogenesis, osteogenesis, and chondrogenesis, similar to the BMPRIa mutants [31
]. Additionally, overexpression of a BMPRIa mutant (SLKD) that lacked a serine AA to prevent binding of CK2 led to increased mineralization via extracellular signal-related kinase/,itogen-activated protein kinase kinase (ERK/MEK) signaling, indicating that the BMP-2 signaling pathway is regulated by CK2 [157
]. This suggests that exogenous BMP-2 is not needed to activate downstream pathways if CK2 inhibitors are present.
3.6. Endocytosis and Degradation of BMP-2 and BMPRs
As stated in previous sections, BMP-2-BMPR complexes can be endocytosed into cells via CCPs, caveolae, or lipid rafts. However, upon endocytosis, the complex continues as a signaling endosome, and is degraded (or recycled) to the plasma membrane [213
]. First, to regulate the signaling activity of BMP-2 after endocytosis, this protein must be deactivated or degraded to prevent continuous expression. To suppress BMP-2 activity, data demonstrated that BMP-2 is ubiquitinated at several lysine residues, initiating its degradation [214
]. Further, if this proteasomal-ubiquitination pathway is inhibited, BMP-2 activity is increased, and the protein is secreted more rapidly from cells [214
]. However, the time-course of BMP-2 degradation and the mechanism of BMP-2 recycling remains unknown and requires further research.
For BMPRs, previous studies demonstrate that BMPRII and BMPRIa are regulated by Dullard, which is a phosphatase, upon endocytosis. When Dullard is inhibited, BMP signaling is enhanced, and when Dullard is active, BMPRIa and BMPRII are deactivated and dephosphorylated to inhibit BMP signaling [150
]. Additionally, once the BMPRs are endocytosed, a ubiquitin ligase named Smurf1 was also identified to ubiquitinate the BMPR complexes and cause degradation [218
]. Together, these proteins regulate BMP-2/BMPR activity intracellularly.
This entry is adapted from 10.3390/jdb8030019